Clinical Trial Goal
To find out if autologous BMT followed by HST-NEETs is safe and works well to treat HIV-related lymphoma
You may be able to join this trial if you:
- Are 15 years old or older
- Have HIV and are being treated with antiretroviral therapies (ART)
- Have lymphoma that has relapsed or is refractory. Some examples include:
- Burkitt lymphoma
- Diffuse large B-cell lymhpoma (DLBCL)
- Hodgkin lymphoma
- Immunoblastic lymphoma
- Plasmablastic lymhpoma
- Primary effusion lymphoma
- Do not have lymphoma in your brain or spinal cord
- Have not an autologous (your own cells) or allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Have not had CAR T-cell therapy
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Carmustine, cytarabine, etoposide and melphalan are chemotherapy (chemo) drugs that block the growth of cancer cells.
HST-NEETS are HIV-1 specific T-cells that target and attack HIV. HST-NEETS are made using your own blood-forming cells, which are then modified in a lab.
HST-NEETS are HIV-1 specific T-cells that target and attack HIV. HST-NEETS are made using your own blood-forming cells, which are then modified in a lab.
First, you’ll have apheresis, a process to collect, separate and save your blood-forming cells.
Before transplant you'll get chemo with 4 standard drugs:
- Carmustine
- Cytarabine
- Etoposide
- Melphalan
On transplant day, your own blood-forming cells are given back to you through an intravenous (IV) infusion.
After transplant, you’ll get:
- HST-NEETs – Given as an IV infusion 1 time
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has not yet approved HST-NEETs after autologous BMT to treat HIV-related lymphoma.
Locations
Sponsors
collaborator: National Heart, Lung, and Blood Institute (NHLBI), collaborator: Blood and Marrow Transplant Clinical Trials Network, collaborator: National Cancer Institute (NCI), collaborator: National Marrow Donor Program, collaborator: Children's National Research Institute, lead: Catherine Bollard
